ETON PHARMACEUTICALS INC

ETONNASDAQ

🏆 #1848 by market capEarnings Aug 13US Equity

$42.05▼ $1.56 (−3.71%)

🌙 After hours$40.87▼ 2.81%Regular close · extended-hours price shown

1h—

24h▼ 3.7%

7d—

14d—

30d—

1y—

🏦Market Cap

$1.15B

Small Cap

📈Revenue Growth (YoY)

+104.9%

High Growth

📊Gross Margin

54.8%

Healthy

💵FCF Margin

17.8%

Healthy

⚖️P/S Ratio

13.2x

Elevated

Otter Score

Weak

No chart data available for ETON.

Trading Snapshot

Day Range: $41.69 – $42.57
52-Week Range: $14.27 – $50.18
Volume: $2.28B
Avg Volume: $2.27B
Shares Outstanding: 27.4M
Next Earnings: Oct 5, 2026

Fundamentals Snapshot

Annual Revenue: $80M
Last Q Revenue: $24M
P/E Ratio: -822.9
P/S Ratio: 13.2x
EPS (TTM): $-0.05
Dividend Yield: 0.00%

Why Investors Own ETON

✓High-growth profile — revenue up +14.4% YoY with expanding US Equity exposure.
✓Healthy economics — 31% gross margin and 18% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$80M▲ +17.9% YoY

Gross Margin (TTM)

31.3%▲ +3.2% YoY

Operating Income (TTM)

$22M▲ +17.9% YoY

Free Cash Flow (TTM)

$15M▲ +17.9% YoY

About ETON PHARMACEUTICALS INC

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

🦦